Related Experiment Video
Updated: Jun 8, 2025

Generation of Cationic Nanoliposomes for the Efficient Delivery of In Vitro Transcribed Messenger RNA
Published on: February 1, 2019
Biologics-based technologies for highly efficient and targeted RNA delivery
Anastasiya Kostyusheva1, Sergey Brezgin2, Natalia Ponomareva2
1Laboratory of Genetic Technologies, Martsinovsky Institute of Medical Parasitology, Tropical and Vector-Borne Diseases, First Moscow State Medical University (Sechenov University), Moscow 119435, Russia.
Researchers developed hybrid nanovesicles (Hybs) for efficient RNA delivery, overcoming limitations in current RNA therapeutics. These novel delivery vehicles show enhanced cellular uptake and therapeutic potential in vitro and in vivo.
Area of Science:
- Biotechnology
- Nanomedicine
- Molecular Biology
Background:
- Growing demand for RNA therapeutics necessitates advanced delivery systems.
- Current RNA delivery methods face challenges with safety and efficiency.
- Extracellular vesicle-mimetic nanovesicles (EMNVs) offer potential but require improved targeting and internalization.
Purpose of the Study:
- To develop novel hybrid nanovesicles (Hybs) for enhanced RNA delivery.
- To engineer EMNVs with tissue-targeting capabilities using truncated CD63 or PTGFRN proteins.
- To evaluate the in vitro and in vivo efficiency and cellular fate of the developed Hybs.
Main Methods:
- Fabrication of hybrid EMNV-liposomes (Hybs).
- Genetic engineering of EMNVs with truncated CD63 or PTGFRN for targeting.
- In vitro and in vivo assessment of nanoparticle internalization and RNA delivery efficiency.
- Comparative analysis of lysosomal colocalization and stability of EMNVs and Hybs.
- Generation of liver-targeting Hybs loaded with small interfering RNA (siRNA).
Main Results:
- Functionalized EMNVs showed >10-fold enhanced in vitro and >2-fold in vivo nanoparticle internalization.
- Hybs achieved >85% RNA delivery efficiency in human and mouse cell lines.
- Hybs demonstrated lysosomal escape over time, unlike EMNVs.
- Liver-targeting Hybs loaded with siRNA showed robust in vitro and in vivo therapeutic efficiency.
Conclusions:
- Developed hybrid nanovesicles (Hybs) represent a significant advancement in RNA delivery technology.
- Engineered EMNVs with targeting proteins enhance cellular uptake and therapeutic efficacy.
- Hybs offer a promising platform for next-generation RNA therapeutics with improved safety and targeting.
Related Concept Videos
Experimental RNAi
RNA Interference
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
Microorganisms in Medicine and Therapeutics
Nucleic Acids
DNA and RNA
The two main types of nucleic acids are deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). DNA is the genetic material in all living organisms, ranging from single-celled bacteria to multicellular mammals. It is in the nucleus of eukaryotes and in the organelles, chloroplasts, and mitochondria. In prokaryotes,...
siRNA - Small Interfering RNAs
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...

